A meta-analysis GWAS of taxane-induced peripheral neuropathy in patients with breast cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full ...

Pfizer said its experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial. Patients with the ...

Financial toxicity, quality of life, symptom burden, and access to resources in early-phase clinical trial (EP-CT) participants. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I.

Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...

Cachexia causes extreme weight loss and muscle wasting. It is a symptom of various chronic conditions such as cancer, chronic renal failure, HIV, and multiple sclerosis. Cachexia predominantly affects ...

Halting the advance of a muscle wasting condition called cachexia, could improve quality of life for cancer sufferers. For many years, oncologists and researchers thought the dramatic weight-loss of ...

Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The experimental ...